Deon Lingervelder, Hendrik Koffijberg, Ron Kusters, Maarten J IJzerman
Pharmacoecon Open. 2021;5(2):157-173.
Point-of-care testing (POCT) is an essential diagnostic technology for optimal patient care. Despite this, its implementation has been slow. In this systematic review, the authors analyse literature on the health economic impact of introducing POCT to assess if poor POCT uptake is related to lack of evidence.
The authors searched 396 publications, of which 44 met the inclusion criteria. The group reported that most evaluations were performed in a primary care setting and that two thirds of the evaluations were on POC tests implemented with a diagnostic purpose. Additionally, more than 75% of evaluations concluded that POCT is recommended for implementation.
The authors found that the uptake of POCT in many countries is low despite health economic evidence indicating its benefits. They concluded that the lack of evidence for POCT is not the primary barrier to its implementation; the majority of evaluations recommend implementation of POCT and that POCT is proven to be a valuable counterpart to traditional laboratory testing.
The full publication can be accessed here.
&copie; 2022 Abbott. Tous les droits sont réservés. Toutes les marques commerciales référencées sont des marques commerciales du groupe de sociétés Abbott ou de leurs propriétaires respectifs.
Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner, Paul Roderick, Toshimi Sairenchi, Ben Schöttker, Anoop Shankar, Michael Shlipak, Marcello Tonelli, Jonathan Townend, Arjan van Zuilen, Kazumasa Yamagishi, Kentaro Yamashita, Ron Gansevoort, Mark Sarnak, David G Warnock, Mark Woodward, Johan Ärnlöv, CKD Prognosis Consortium
Estimated glomerular filtration rate and albumin-to-creatinine ratio testing for cardiovascular risk assessmentenAccéder maintenant
Johan Sundström, Johan Bodegard, Andreas Bollmann, Marc G Vervloet, Patrick B Mark, Avraham Karasik, Tiago Taveira-Gomes, Manuel Botana, Kåre I Birkeland, Marcus Thuresson, Levy Jäger, Manish M Sood, Gijs VanPottelbergh, Navdeep Tangri; on behalf of the CaReMe CKD Investigators
Prevalence, outcomes and cost of chronic kidney diseaseenAccéder maintenant